Utah Medical Products, Inc. Reports Audited Financial Performance for Fourth Quarter and Year 2017

Utah Medical Products (Nasdaq:UTMD) concluded an outstanding year in 2017 in which it harvested distribution changes that had been in the making for several years.
As quoted in the press release:

Although UTMD substantially exceeded management expectations for 2017 financial performance, the results became masked by the recognition of a one-time U.S. repatriation tax (REPAT) on foreign subsidiary cash and cumulative earnings (E&P) in the fourth quarter (4Q) of the year.

Click here to read the full press release.